Filing Flows › VitaNova Life Sciences (VNOV) › Q3 FY26
VitaNova Life Sciences (VNOV) Q3 FY26 earnings results (third quarter fiscal 2026)
10-Q filed Mar 16, 2026
VitaNova Life Sciences (VNOV) reported revenue of $710K for the third quarter fiscal 2026 (Q3 FY26), +130% from a year earlier and +66% from the quarter before. Operating margin was 6.6%, net loss $44K (6.3% of revenue).
VitaNova Life Sciences, Q3 FY26: revenue $710K (+130% year over year), operating margin 6.6%, net loss $44K, operating cash flow −$90K. The chart follows the revenue to costs, profit and cash.
| Q3 FY26 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $710K | +66% | +130% |
| Operating profit | $47K | -53% | -57% |
| Net earnings | −$44K | -224% | -161% |
| Operating cash flow | −$90K | -142% | -143% |
What changed
Revenue was $710K in Q3 FY26, up 130% year over year and up 66% from the previous quarter. Sale of Healthcare Products was the largest line at 99% of revenue. Sale of Healthcare Products added $404K year over year (up 134%), 101% of the total change. Consulting Service Income declined 39%.
Gross margin was 44.6%, down 16.8 points from Q3 FY25. Operating profit was $47K, a 6.6% margin (down 28.7 points year over year). Operating profit fell $62K even though revenue rose $401K versus Q3 FY25, so costs grew faster than sales. Operating expenses grew 235% against revenue growth of 130%. The fastest-growing cost line was General & admin (+616%). The quarter ended with a net loss of $44K, after a profit of $36K the previous quarter.
Operating cash flow was −$90K. Working capital and other items used $46K.
Questions
What was VitaNova Life Sciences' revenue in the third quarter fiscal 2026?
VitaNova Life Sciences (VNOV) reported revenue of $710K for the third quarter fiscal 2026 (Q3 FY26), +130% from a year earlier and +66% from the quarter before.
Was VitaNova Life Sciences profitable in the third quarter fiscal 2026?
Operating profit was $47K (6.6% of revenue) and net loss $44K.